IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action

• Main Authors: Lecour, Sandrine, Andreadou, Ioanna, Bøtker, H.E., Davidson, Sean M., Heusch, Gerd, Ruiz-Meana, Marisol, Schulz, Rainer, Zuurbier, Coert J., Ferdinandy, Peter, Hausenloy, Derek J., Adamovski, P., Batirel, S., Barteková, M., Bertrand, L., Beauloye, C., Biedermann, D., Borutaite, V., Chlopicki, S., Dambrova, M., Devaux, Y., Di Lisa, F., Djuric, D., Erlinge, D., Falcao-Pires, I., Galatou, E., Garcia-Sosa, A., Girao, H., Giricz, Z., Gyongyosi, M., Healy, D., Jakovljevic, V., Jovanic, J., Kararigas, G., Kerkal, R., Kolar, F., Kwak, B., Leszek, P., Liepinsh, E., Lonborg, J., Longnus, S., Marinovic, J., Muntean, D.M., Nezic, L., Ovize, M., Pagliaro, P., Da Costa Gomes, C.P., Pernow, J., Persidis, A., Pischke, S.E., Podesser, B., Poto?njak, I., Prunier, F., Ravingerova, T., Serban, A., Slagsvold, K., van Royen, N., Turan, B., Vendelin, M., Walsh, S., Zidar, N., Yellon, D., on behalf ofthe European Union-CARDIOPROTECTION COST ACTION CA16225.
• 其他作者: DUKE-NUS MEDICAL SCHOOL
• 格式: Review
• 出版: Springer Science and Business Media Deutschland GmbH 2022
• 主題: Cardioprotection; Drug development; Infarction; Ischemia; Reperfusion
• 在線閱讀: https://scholarbank.nus.edu.sg/handle/10635/232890

10.1007/s00395-021-00893-5